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Background: Suboptimal device programming is among the reasons for reduced response to 
cardiac resynchronization therapy (CRT). However, whether systematic optimization is 
beneficial remains unclear, particularly late after CRT implantation. The aim of this single-
center cohort study was to assess the effect of systematic atrioventricular delay (AVD) 
optimization on echocardiographic and device parameters. 
Methods: Patients undergoing CRT optimization at the University Hospital Zurich between 
March 2011 and January 2013, for whom a follow-up was available, were included. AVD 
optimization was based on 12-lead electrocardiography (ECG) and echocardiographic left 
ventricular inflow characteristics. Parameters were assessed at the time of CRT optimization 
and follow-up, and were compared between patients with AVD optimization (intervention 
group) and those for whom no AVD optimization was deemed necessary (control group). 
Results: Eighty-one patients with a mean age of 64 ± 11 years were included in the analysis. 
In 73% of patients, AVD was deemed suboptimal and was changed accordingly. After a 
median follow-up time of 10.4 (IQR 6.2 to 13.2) months, the proportion of patients with 
sufficient biventricular pacing (> 97% pacing) was greater in the intervention group (78%) 
compared to controls (50%). Furthermore, AVD adaptation was associated with an 
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improvement in interventricular mechanical delay (decrease of 6.6 ± 26.2 ms vs. increase of 
4.3 ± 17.7 ms, p = 0.034) and intraventricular septal-to-lateral delay (decrease of 0.9 ± 48.1 
ms vs. increase of 15.9 ± 15.7 ms, p = 0.038), as assessed by tissue Doppler imaging. 
Accordingly, a reduction was observed in mitral regurgitation along with a trend towards 
reduced left ventricular volumes. 
Conclusions: In this “real-world” setting systematic AVD optimization was associated with 
beneficial effects regarding biventricular pacing and left ventricular remodeling. These data 
show that AVD optimization may be advantageous in selected CRT patients. 
Key words: cardiac resynchronization therapy, atrioventricular delay, biventricular 




Cardiac resynchronization therapy (CRT) is a life-saving treatment in selected patients 
with symptomatic heart failure and reduced ejection fraction (HFrEF) [1–3]. In patients with 
persistent symptoms (New York Heart Association II to ambulatory IV) on optimal medical 
therapy, a left ventricular ejection fraction (LVEF) of 35% or less, and a wide QRS complex 
(> 130 ms), CRT has been shown to prolong life and reduce the risk for recurrent heart failure 
(HF) hospitalizations [4–8]. However, about one third of patients remain unresponsive to 
biventricular pacing and do not exhibit improvement in clinical or hemodynamic parameters 
[5, 6]. Several factors may account for this unsatisfactory therapeutic response in this relevant 
proportion of patients. Apart from ineffective synchronization secondary to suboptimal left 
ventricular (LV) lead placement or extensive scar tissue, and indeliberate patient selection 
remains a major source of error [7, 9]. However, even after correct LV lead placement and in 
the absence of extensive scar tissue, response to CRT may not be evident. Such therapy 
failure may be attributed to suboptimal device programming, specifically with regard to the 
atrioventricular delay (AVD) and interventricular (VV) interval [10, 11]. Yet, whether 
systematic AVD optimization is of prognostic benefit, remains unclear. To date, a number of 
studies suggest an improvement of clinical, echocardiographic and hemodynamic parameters 
after AVD optimization. However, the number of patients is very low and follow-up times are 
short [12–15].  
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At the documented institution, a standard protocol of echocardiography- and 12-lead 
electrocardiography (ECG)-guided device optimization after CRT implantation was 
implemented. It was previously demonstrated that a majority of patients undergoing CRT 
optimization after implantation presented with suboptimal device settings, particularly 
regarding AVD [16]. The aim of this study was to evaluate the clinical course after AVD 
optimization and to study whether patients, in whom the AVD was changed, fared better than 
those in whom the AVD was left unchanged in this real-world setting. 
 
METHODS 
All patients with a CRT-device who underwent CRT optimization at the documented 
device clinic between March 2011 and January 2013 and in whom at least one follow-up 
including echocardiography was available were included. CRT devices were implanted 
according to standard protocols at the University Heart Center Zurich. Patients for CRT 
implantation were selected based on current guideline recommendations [17]. After 
implantation, a baseline CRT-optimization was performed on a routine basis, patients referred 
for CRT implantation from elsewhere underwent baseline optimization in cases of explicit 
referral. Baseline optimization included a comprehensive device optimization protocol with a 
complete clinical assessment by a HF specialist, a device interrogation, 12-lead ECGs of 
intrinsic and paced (BiV, RV, LV) rhythms, and a complete echocardiograph exam with 
optimization of AVD, if deemed necessary [16]. After baseline optimization, follow-up CRT-
optimization was performed in cases of non-response or signs of disease progression, i.e. 
patients were referred for follow-up CRT optimization if there was a decrease or insufficient 
increase of LVEF after unexplained HF decompensation or in cases of unexplained 
progressive decline in exercise capacity. 
The need for optimization of AVD was based on the degree of QRS fusion on 12-lead 
ECG and the presence of LV inflow truncation or fusion as assessed by pulsed wave Doppler 
echocardiography. For detection of electrical fusion, QRS morphology was assessed on 12-
lead ECG during intrinsic rhythm, in biventricular stimulated VVI mode (representing “true” 
biventricular pacing), during right/left ventricular pacing only, and during CRT pacing under 
current settings. AVD was then programmed for as long as possible without signs of fusion 
with intrinsic conduction. Optimal LV filling was subsequently determined according to the 
iterative method [18, 19], i.e., AVD was shortened in steps of 20 ms under parallel assessment 
of QRS morphology on a 12-lead ECG and mitral inflow on pulsed wave Doppler 
echocardiography until truncation of the A-wave indicated impairment of LV filling. In a 
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third step, AVD was increased in steps of 10 ms until an optimal separation of E and A wave 
occurred. This was considered an optimal atrioventricular coupling. 
For the current study, clinical, echocardiographic and device parameters at the time of 
echocardiography, a 12-lead ECG-guided CRT optimization (baseline visit) and at the time of 
the follow-up visit were analyzed. Parameters were compared between patients, in whom the 
AVD was changed at baseline (“intervention group”) and those, in whom no adaptation of the 
AVD was made (“control group”) (Fig. 1, Suppl. Fig. 1). Reasons for not changing the AVD 
were either an interval that was deemed optimal as assessed by the method described above, 
or if a change in AVD would lead to new QRS fusion or truncation of the A wave. 
 
Statistical analysis 
Continuous variables are expressed as mean and standard deviation; categorical variables 
are expressed as proportions. Within-group comparisons (baseline vs. follow-up) were 
performed using the paired Student t-test for continuous variables and the paired Wilcoxon 
signed-rank tests for categorical variables. Between-group comparisons (intervention group 
vs. control group) were done using the unpaired Student t-test and the Mann-Whitney-U-test, 
where applicable. Distribution of data was assessed by the Shapiro-Wilk test and quantile-
quantile (Q-Q) plots. Both data at baseline optimization and at follow-up as well as 
differences in parameters over time were assessed for normal distribution. Proportions were 
compared using Chi-square tests. Statistical significance was accepted for p < 0.05. All p-
values are two-sided. Statistical analyses were performed using SPSS version 22. 
 
RESULTS 
Eighty-one patients undergoing baseline CRT optimization between March 2011 and 
January 2013 and in whom a consecutive follow-up was available were included in the 
analysis. Baseline characteristics are summarized in Table 1. With the exemption of atrial 
fibrillation (AF), which was absent in the intervention group, and complete atrioventricular 
block, which was more frequent in the control group, no significant differences were present 
(Table 1). Median time between CRT implantation and baseline CRT-optimization was 1.7 
(IQR 0.4 to 4.2) years. Median follow-up time between baseline optimization and follow-up 
was 10.4 (IQR 6.2 to 13.2) months. Out of 81 patients, 3 patients were hospitalized for HF 
during follow-up (2 in the intervention group, 1 in the control group). At baseline, 59 (73%) 
patients presented with AVD, which was deemed suboptimal either secondary to the presence 
of QRS fusion on a 12-lead ECG or due to unfavorable LV-filling patterns as assessed by 
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echocardiography [16]. In these patients, AVD was reprogrammed according to the method 
described above; in the majority of these patients (n = 42, 52%) AVD was decreased, 
secondary to QRS fusion and/or LV inflow fusion. In 17 (21%) patients AVD was prolonged 
secondary to LV inflow truncation. Accordingly, the average AVD was significantly shorter 
at follow-up compared to baseline (120 ± 20 ms at baseline and 100 ± 29 ms at follow-up, p = 
0.001). 12 (15%) patients were in AF.  
In the overall population, clinical parameters did not change significantly between 
baseline and the follow-up visit. The proportion of patients with New Year Heart Association 
(NYHA) class II or higher was 79% (n = 58/73) at baseline and 76% (n = 57/75) at follow-up 
(p = 0.109). 
Interestingly, biventricular pacing increased in patients after AVD adjustment over time. 
While there was no difference in biventricular pacing at baseline, the proportion of patients 
with a biventricular pacing rate of > 97% increased significantly by the time of follow-up 
(78% in the intervention group vs. 50% in the control group, p = 0.021; Fig. 2). As proof of 
concept, reassessment of biventricular pacing at follow-up was performed after exclusion of 6 
patients with AF and intact atrioventricular conduction. Biventricular pacing proportions 
remained significantly higher in the intervention compared to the control group (mean 
biventricular pacing rate: 94.5 ± 6.8% in the control group, 97.5 ± 4.0% in the intervention 
group, p = 0.022; percentage of patients with > 97% biventricular pacing: 44% in the control 
group, 78% in the intervention group, p = 0.031; Suppl. Table 1). 
Moreover, both interventricular mechanical delay (IVMD) and septal to lateral delay 
(SLD), as assessed by tissue Doppler imaging (TDI), decreased in the intervention group 
(AVD changed) compared to the control group (AVD unchanged), in which both IVMD and 
SLD increased from baseline to follow-up (Fig. 3). Although left ventricular ejection fraction 
was not different between the intervention and the control group at follow-up (Fig. 4A), a 
trend was observed towards reduced end-diastolic LV volumes (Fig. 4B) in the intervention 
group. Along this line, the proportion of patients with mitral regurgitation, which did not 
differ between both groups at baseline (Fig. 4C), decreased in the intervention group while it 
increased in the control group resulting in a significant difference at follow-up (Fig. 4D).  
 
DISCUSSION 
This retrospective is a single-center cohort study in a real-world setting. AVD 
optimization was associated with an improvement of biventricular pacing, inter- and 
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intraventricular synchronicity, as well as a reduction in mitral regurgitation along with a trend 
towards reduced end-diastolic LV volumes. 
These results corroborate previous findings from several smaller studies with shorter 
follow-up [12–14]. However, the role of regular evaluation and adjustment of the 
atrioventricular interval in patients with CRT and the method of AVD optimization remain a 
matter of debate [20]. In contrast to other studies, the prospective, randomized, controlled 
SMART-AV trial showed no benefit of general AVD optimization as opposed to a fixed AVD 
of 120 ms with regard to the primary outcome of LV end-systolic volume at 6 months [21]. It 
was concluded that regular AVD assessment and optimization was not necessary and a fixed 
interval of 120 ms would suffice. However, these results may not apply to selected 
individuals, especially those with a suboptimal response to CRT in combination with 
suboptimal diastolic ventricular filling. Indeed, Mullens et al. [11] observed suboptimal AVD 
settings in 45% of those patients who suffered from persistent advanced HF symptoms and/or 
adverse remodeling after CRT implantation. Furthermore, a sub-analysis of MADIT-CRT, 
one of the guideline-defining, large randomized, controlled trials, demonstrated that patients 
programmed to a short AVD (< 120 ms) had a reduced risk of HF or death over the 3 years 
following CRT implantation compared to those patients with an AVD > 120 ms, further 
indicating a role of AVD settings on long-term outcome in selected CRT patients [22]. 
Finally, a post-hoc analysis of the CLEAR study demonstrated an improved outcome for the 
composite endpoint of all-cause mortality, HF hospitalization, NYHA class and quality of life 
with regular, systematic AVD optimization as opposed to “non-systematic” optimization, 
irrespective of the optimization method applied [23].  
Although an assessment of the effect of CRT optimization on morbidity and mortality 
was beyond the scope of this real-world study, the data support a potential role for CRT 
optimization with regard to long-term outcome. The present results further underline the 
importance of the evaluation and adjustment of device settings, given that a substantial part of 
CRT patients presented with inadequate atrioventricular intervals at baseline.  
A high percentage of biventricular pacing is associated with an improved outcome in 
CRT patients [24]. Koplan et al. [25] demonstrated that the greatest benefit in reduction of HF 
hospitalization and all-cause mortality was achieved with a biventricular pacing above 92%. 
The rationale for an even higher proportion of biventricular pacing was provided by Hayes et 
al. [26] in a cohort of over 30,000 patients, where mortality was found to be inversely related 
with the percentage of biventricular pacing. Since a reduced percentage of biventricular 
pacing is among the main reasons for suboptimal response to CRT [11], these data imply that 
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regular assessments and efforts to increase biventricular pacing are central. However, there 
are no data assessing this hypothesis prospectively, and whether certain interventions to 
improve biventricular pacing such as antiarrhythmic therapy in patients with AF truly impact 
hard clinical outcomes remains elusive.  
Loss of biventricular pacing can occur as a result of a long AVD due to intrinsic 
atrioventricular conduction. In such patients, shortening of AVD may increase the degree of 
biventricular pacing [24–26]. In the present study, patients in whom the AVD was changed 
(mostly shortened) during CRT optimization had a higher percentage of biventricular pacing 
at follow-up. The favorable development of hemodynamic parameters in the intervention 
group may well be a consequence of the higher biventricular pacing proportion in these 
patients. As adaptation of AVD in order to prevent intrinsic conduction can be performed on 
the basis of QRS morphology on 12-lead ECG, this raises the question, if echocardiographic 
assessment during AVD optimization is necessary. It is however important to note that 
ensuring constant biventricular pacing based on 12-lead ECG alone may lead to programming 
excessively short AV delays in order to prevent QRS fusion. In this context, 
echocardiographic monitoring of mitral inflow is crucial in order to avoid impaired left 
ventricular filling. Herein, echocardiography was therefore regarded as an essential 
component in the process of AVD optimization. 
Taken together, the present findings support the role of systematic AVD optimization to 
achieve the highest possible percentage of biventricular stimulation and improve 
hemodynamic parameters. The absolute effect of this improvement, however, was small and it 
remains to be determined whether this will translate into a reduction in morbidity and 
mortality. 
 
Limitations of the study 
This study has to be interpreted in light of several limitations, most of which are inherent 
to any “real-world” registry study. All patients analyzed were recruited at a single center, 
which may introduce a selection and/or referral bias, and may therefore not reflect the 
situation in other healthcare facilities.  
Furthermore, the control group included 12 patients with AF. In CRT-patients AF can 
lead to loss of biventricular pacing secondary to high ventricular rates. Importantly, several 
studies have shown similar benefit of CRT in patients with AF and those in sinus rhythm [27–
30]. However, more recent evidence points to a worse prognosis of CRT in the context of AF 
[31, 32]. This is primarily due to high ventricular rates and consecutive electrical fusion or 
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loss of biventricular pacing, highlighting the importance of adequate rate control [33]. This 
was evident in the CERTIFY registry by Gasparini et al. [33], in which CRT-patients in sinus 
rhythm were compared to CRT-patients with AF either after atrioventricular junction ablation 
(AVJA) or without AVJA [34]. After a median follow-up of 37 months, mortality was similar 
between AF patients after AVJA and patients in sinus rhythm, while AF patients on medical 
rate control alone had a worse outcome compared to both patients in sinus rhythm and 
patients with AF and AJVA. This implies that patients with AF and complete atrioventricular 
block derive equivalent benefit from CRT as do patients in sinus rhythm [33]. Out of the 12 
patients with AF in the present cohort, 6 patients had intact intrinsic conduction. Upon 
exploratory exclusion of these patients, the difference in biventricular pacing between the 
intervention group and the control group remained significantly different. It can therefore be 
assumed that the difference in biventricular pacing proportions at follow-up were not driven 
by patients in AF. 
Since this study ought to reflect real-world data, not all variables are distributed evenly 
between groups. Importantly, there was a higher proportion of patients with complete 
atrioventricular block in the control group (50% vs. 7%), an effect due to the fact that in these 
patients AV optimization is oftentimes not necessary as no fusion with intrinsic conduction 
can occur. Few data exist on the direct comparison between CRT-patients with LBBB and 
those with complete atrioventricular block. However, in patients with atrioventricular block 
and reduced LVEF biventricular pacing has been shown to reduce the risk of mortality and 
morbidity and lead to better clinical outcomes [35]. In the absence of intrinsic conduction, 
complete atrioventricular block is associated with higher biventricular pacing proportions. 
Therefore,  if present, confounding, may lead to an underestimation of the difference in 
biventricular pacing proportions in the context of this study. However, as this study was 
intended to reflect a real-world setting, the current study refrained from excluding patients 
from the analyses wherever possible. Of note, QRS-width, which is the primary determinant 
of response in CRT [7], was evenly distributed among the groups in this real-world cohort. 
Finally, and as with every registry study, residual confounding between groups may have 
contributed to the findings; as such, only associations and no causality may be inferred [36]. 
This notwithstanding, the data herein does reflect a “real-world” setting of CRT patients, 
which may contribute important insight into evolving therapy concepts such as CRT 






The present study results imply that AVD optimization may result in an increased 
biventricular pacing percentage, which has been shown to be associated with better 
hemodynamic parameters and reduced mortality. Whether these hypotheses hold true, remains 
to be determined in a well-controlled randomized setting. 
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Table 1. Parameters at baseline during cardiac resynchronization therapy-optimization. 
Parameters Overall population (n 
= 81) 
Control group (n = 
22) 
Intervention group 
(n = 59) 
P 
Age at implantation (years) 64 ± 11  63 ± 16  64 ± 9  0.725 
Men (n/total) 63/81 (78%) 17/22 (77%) 46/59 (78%) 0.947 
Co-morbidities 
Diabetes mellitus 20/80 (25%) 7/22 (31.8%) 13/58 (22.4%) 0.386 
Hypertension 44/81 (54.3%) 13/22 (59.1%) 31/59 (52.5%) 0.87 
Dyslipidemia 45/81 (55.6%) 13/22 (59.1%) 32/59 (54.2%) 0.875 
13 
 
Coronary artery disease 32/81 (39.5%) 8/22 (36.4%) 24/59 (40.7%) 0.724 
Atrial fibrillation 12/81 (15%) 12/22 (55%) 0/59 (0%) < 0.001* 
Medication 
ACEI/ARBs  79/80 (98.8%) 21/22 (96%) 58/58 (100%) 0.102 
Beta-blockers 77/80 (96.3%) 21/22 (96%) 56/58 (96.6%) 0.818 
Calcium channel blockers 6/80 (7.5%) 0/22 (0%) 6/58 (10%) 0.117 
Spironolactone 47/80 (58.8%) 12/22 (55%) 35/58 (60%) 0.638 
Diuretics 69/80 (86.3%) 21/22 (96%) 48/58 (83%) 0.141 
Digitalis 10/80 (12.5%) 4/22 (18.2%) 6/58 (10.3%) 0.344 



























Weight [kg] 81 ± 19  85 ± 21  80 ± 18  0.32 
Systolic BP [mmHg] 118 ± 18  118 ± 18  118 ± 18  0.955 
NT-proBNP [pg/mL] 1462 ± 1964  2015 ± 2186  1256 ± 1856  0.152 
Echocardiographic parameters 
LVEF [%] 38 ± 10  38 ± 11  37 ± 9  0.78 
EDVI [mL/m2] 88 ± 38  85 ± 39  89 ± 37  0.697 
IVMD [ms] 17.3 ± 28.0  12.9 ± 20.6  18.8 ± 30.0  0.41 
TDI septal to lateral [ms] 41.7 ± 44.7  15.5 ± 51.2  48.3 ± 40.8  0.013* 
TDI anteroseptal to 
inferolateral [ms] 
38.2 ± 48.4  18.8 ± 48.8 42.8 ± 47.7  0.108 
ECG and device parameters    
Biventricular pacing [%] 95.6 ± 9.6  93.8 ± 13.0  96.3 ± 8.0  0.304 




















Complete AVB 15/80 (19%) 11/22 (50%) 4/58 (7%) < 0.001* 
QRS width [ms] 150 ± 28  142 ± 25  152 ± 28  0.264 
PQ interval [ms]** 184 ± 28 172 ± 40  185 ± 27  0.38 
Sensed AV interval [ms] 112 ± 20  122 ± 22  110 ± 19  0.156 
Paced AV interval [ms] 136 ± 23  146 ± 31  135 ± 22  0.223 
VV delay [ms] 10 ±17  11 ± 21 9 ± 16  0.78 
VV delay changed 16/81 (20%) 2/22 (9%) 14/59 (24%) 0.141 
Continuous variables are presented as mean ± standard deviation; categorical variables are presented as 
proportions. *Complete AVB excluded. **Patients with complete AVB and patients with AF excluded 
ACEI/ARB — angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker; AV — atrioventricular; 
AVB — atrioventricular block; BP — blood pressure; CRT — cardiac resynchronization therapy; EDVI — end-
diastolic volume index; IVCD — intraventricular conduction delay; IVMD — interventricular mechanical delay; 
LBBB — left bundle branch block; LVEF — left ventricular ejection fraction; NYHA — New York Heart 





Table 2. Parameters in patients with changed atrioventricular delay and patients with 
unchanged atrioventricular delay at follow-up visit. 






















Weight (kg) 83 ± 24   81 ± 19  0.603 
Systolic BP [mmHg] 115 ± 17  120 ± 16  0.331 
NT-proBNP [pg/mL] 1674 ± 1446  1092 ± 1602  0.169 
Echocardiographic parameters 
LVEF [%] 39 ± 12  39 ± 10  0.903 
EDVI [mL/m2] 90 ± 43  87 ± 38  0.794 
IVMD [ms] 16.0 ± 20.6  12.8 ± 22.3  0.553 
TDI septal to lateral [ms] 31.9 ± 44.5  47.6 ± 46.2  0.184 
TDI anteroseptal to 
inferolateral [ms] 
36.2 +/- 52.3  44.1 ± 42.5  0.515 
Electrocardiography and device parameters 
Biventricular pacing [%] 95.3 ± 6.0  97.5 ± 4.0   0.034* 
















Complete AVB 11/22 (50%) 4/58 (7%) < 0.001* 
QRS width [ms] 141 ± 31  147 ± 23  0.47 
PQ interval [ms]** 189 ± 40 195 ± 41 0.92 
Sensed AV interval [ms] 121.8 ± 20.4  96.4 ± 28.2  0.006* 
Paced AV interval [ms] 144.6 ± 29.8  130.7 ± 30.5  0.17 
VV delay [ms]  7.6 ± 15.4   15.7 ± 22.1  0.144 
Continuous variables are presented as mean ± standard deviation; categorical variables are presented as 
proportions. *Complete AVB excluded. **Patients with complete AVB and patients with AF excluded 
AV — atrioventricular; AVB — atrioventricular block; BP — blood pressure; CRT — cardiac resynchronization 
therapy; EDVI — end-diastolic volume index; IVCD — intraventricular conduction delay; IVMD — 
interventricular mechanical delay; LBBB — left bundle branch block; LVEF — left ventricular ejection fraction; 
NYHA — New York Heart Association; RBBB — right bundle branch block; TDI — tissue Doppler imaging; 









Figure 1. Follow-up flow chart; AVD — atrioventricular delay; CRT — cardiac 
resynchronization therapy. 
 
Figure 2. Distribution of biventricular pacing proportions before and after atrioventricular 
delay (AVD) optimization. Comparison of the intervention (AVD changed) and control (AVD 
unchanged) group; A. Assessment at baseline; B. Assessment at follow-up. Mann-Whitney U 
tests.  
 
Figure 3. Interventricular mechanical and septal-to-lateral delay in the intervention 
(atrioventricular delay [AVD] changed) and control (AVD unchanged) group; A. 
Interventricular mechanical delay; B. Septal to lateral delay. Box plots indicate interquartile 
ranges, whiskers indicate minima and maxima. Mann-Whitney U tests.  
 
Figure 4. Reverse remodeling upon adapting atrioventricular delays (AVD); A, B. Change in 
left ventricular ejection fraction (LVEF) and left ventricular end-diastolic volume index 
(LVEDVI), respectively, in the intervention (AVD changed) and control group (AVD 
unchanged) over time. Box plots indicate interquartile ranges, whiskers indicate minima and 
maxima; C. Mitral regurgitation at baseline; D. Mitral regurgitation at follow-up. Mann-
Whitney U tests. 
 




